Bandaram Pharma Packtech passes all five resolutions at FY26 AGM

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • All five resolutions passed unanimously at Bandaram Pharma's FY26 AGM
  • Total votes polled stood at 13,560,514 with zero votes against
  • Public shareholder voting participation remained low at approximately 34%
powered bylight_fuzz_icon
51793418

*this image is generated using AI for illustrative purposes only.

Bandaram Pharma Packtech Limited concluded its Annual General Meeting for FY26 on September 24, 2026, with all five proposed resolutions passed unanimously. The meeting, held via video conference, saw a total of 37 members participate electronically.

The agenda included the adoption of audited standalone and consolidated financial statements for the year ended March 31, 2026. Members also approved the reappointment of Mr. Bhandaram Premasai Reddy as a director retiring by rotation and the reappointment of M/s. M.M. Reddy & Co. as statutory auditors.

Special business approved

A special resolution was passed regarding the reappointment of Mr. Suryaprakasa Rao Bommisetti as an Independent Director. The company disclosed that promoters and promoter group members had an interest in this specific resolution.

Voting participation details

Voting results indicated high promoter participation and moderate public engagement. Promoters voted on 100% of their holding, while non-institutional public shareholders voted on approximately 34.26% of their holding. No votes were cast against any resolution.

Resolution Type Votes Polled Votes in Favour Votes Against Result
Ordinary (Financials) 13,560,514 13,560,514 0 Passed
Ordinary (Director Reappt.) 13,560,514 13,560,514 0 Passed
Special (Ind. Dir. Reappt.) 13,560,514 13,560,514 0 Passed

What the Numbers Show

The voting data reveals a significant divergence in shareholder engagement between promoter groups and public investors. While promoters cast votes on 100% of their 11,262,084 shares, non-institutional public shareholders participated on only 2,298,430 out of 6,709,239 shares held. This results in a public participation rate of roughly 34%, compared to full participation from the promoter group, highlighting a concentration of voting power among insiders.

Historical Stock Returns for Bandaram Pharma Packtech

1 Day5 Days1 Month6 Months1 Year5 Years
+1.01%+3.71%+16.57%-20.46%-34.70%-8.19%

How might the 34% public shareholder participation rate impact Bandaram Pharma Packtech's future corporate governance ratings and institutional investor confidence?

What specific strategic initiatives or capital expenditure plans were outlined in the FY26 financial statements that could drive growth in the upcoming fiscal year?

Given the unanimous approval and lack of dissenting votes, how will the company address potential regulatory scrutiny regarding the concentration of voting power among promoters?

Bandaram Pharma Packtech
View Company Insights
View All News
like19
dislike

Bandaram Pharma Packtech Q4FY26 Results: Net loss widens 728% YoY

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Standalone net loss widened to ₹116.05 lakh from profit of ₹14.00 lakh in FY25
  • Consolidated revenue jumped 70.2% to ₹6,292.32 lakh driven by subsidiary operations
  • Consolidated net profit declined 71.7% to ₹28.12 lakh despite revenue growth
  • AGM scheduled for September 24, 2026, to approve FY26 financials and director appointments
  • No dividend declared for the financial year ended March 31, 2026
powered bylight_fuzz_icon
49825979

*this image is generated using AI for illustrative purposes only.

Bandaram Pharma Packtech has scheduled its Annual General Meeting for Thursday, September 24, 2026, to transact business including the adoption of financial statements for FY26. The meeting was initially planned for September 18 but was postponed due to certain circumstances. Shareholders will vote on ordinary and special resolutions via video conferencing.

Financial Performance

On a standalone basis, the company reported a net loss of ₹116.05 lakh for FY26, a significant deterioration from the net profit of ₹14.00 lakh in the previous year. Revenue from operations declined 10.4% to ₹1,095.99 lakh from ₹1,222.83 lakh. Total expenses remained relatively flat at ₹1,212.63 lakh compared to ₹1,213.12 lakh in FY25.

Consolidated results showed a different trajectory. Group revenue surged 70.2% to ₹6,292.32 lakh from ₹3,696.37 lakh. However, consolidated net profit fell 71.7% to ₹28.12 lakh from ₹99.38 lakh. The divergence between standalone losses and consolidated profits highlights the contribution of subsidiaries, particularly VSR Paper and Packaging Limited, which reported a turnover of ₹5,313.08 lakh.

Metric Standalone FY26 Standalone FY25 Consolidated FY26 Consolidated FY25
Revenue (₹ lakh) 1,095.99 1,222.83 6,292.32 3,696.37
Net Profit (₹ lakh) (116.05) 14.00 28.12 99.38
Total Expenses (₹ lakh) 1,212.63 1,213.12 6,002.05 3,414.20

What the Numbers Show

The standalone entity incurred an operating loss before tax of ₹116.03 lakh, driven by cost of materials consumed at ₹1,060.43 lakh against revenue of ₹1,095.99 lakh. This indicates thin margins in the core trading business. Conversely, the consolidated group generated an operating profit before tax of ₹44.13 lakh. The primary driver of this profitability is the subsidiary VSR Paper and Packaging Limited, which contributed significantly to the top line while the holding company struggled with standalone operational efficiency. The acquisition of Craftsmart Products Private Limited, now a wholly-owned subsidiary, added ₹136.40 lakh to consolidated revenue but incurred a net loss of ₹45.82 lakh.

Corporate Actions

The Board proposed the reappointment of M/s. M.M. Reddy & Co. as statutory auditors for a second term of three years. Remuneration is fixed at ₹2,00,000 per annum plus taxes. Mr. Suryaprakasa Rao Bommisetti seeks reappointment as an Independent Director for a five-year term effective from March 7, 2027. Mr. Bhandaram Premsai Reddy retires by rotation and offers himself for re-appointment as a Non-Executive Director.

The company increased its authorized share capital from ₹12 crore to ₹19 crore during the year. Paid-up capital rose to ₹17.97 crore following the preferential allotment of shares to acquire Craftsmart Products Private Limited. No dividend was recommended for FY26.

Historical Stock Returns for Bandaram Pharma Packtech

1 Day5 Days1 Month6 Months1 Year5 Years
+1.01%+3.71%+16.57%-20.46%-34.70%-8.19%

What specific strategic initiatives will Bandaram Pharma Packtech implement to reverse the standalone operating loss and improve core trading margins in FY27?

How does the acquisition of Craftsmart Products Private Limited align with the company's long-term growth strategy, and when is it expected to turn profitable?

Given the significant divergence between standalone losses and consolidated profits, what is the management's plan to enhance the operational efficiency of the holding company?

Bandaram Pharma Packtech
View Company Insights
View All News
like15
dislike

More News on Bandaram Pharma Packtech

1 Year Returns:-34.70%